Compare IDEXX Laboratories, Inc. (IDXX) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JetBlue Airways Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while JetBlue Airways Corporation trades at $3.84 (market cap $1.48B). The key difference: IDEXX Laboratories, Inc. is far larger — about 27.3× JetBlue Airways Corporation's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 30,275,693). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and JetBlue Airways Corporation for 44 Days on average.
| IDXX | JBLU | |
|---|---|---|
Market Cap | $40.43B | $1.48B |
Volume | 692,164 | 30,275,693 |
Sector | Health | Industrials |
52-Week High | $766.68 | $6.46 |
52-Week Low | $504.70 | $3.84 |
Typical Hold Time | 46 Days | 44 Days |
Enterprise Value | $41.32B | $8.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
JetBlue (JBLU) trades at $3.92, down 1.26% today, reflecting ongoing operational challenges. The airline faces persistent profitability issues with a net income margin of -9.32% and negative ROE of -44.36%. Recent Q2 2026 earnings beat expectations but followed two consecutive misses. Technical indicators show bearish momentum with the stock trading near key support levels. The company continues expansion efforts with new Colombia routes while grappling with high fuel costs and capacity constraints.
Investment outlook remains cautious given sustained losses and high debt levels. The consensus price target of $5.89 offers 50% upside potential, but execution risks from fuel price volatility and competitive pressures persist. Analyst sentiment leans neutral with 62% hold ratings, suggesting limited near-term catalysts for significant price appreciation despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
